Project Grant R34AT013641
- The National Institute of General Medical Sciences awarded the Trustees of Dartmouth College $449,625 under the Biomedical Research and Research Training program (CFDA 93.859) on August 5, 2026, to develop and validate digital biomarkers of postoperative pain derived from smartphones, wearable devices, and other digital health technologies. Over five years through March 31, 2031, the recipient's laboratory at Dartmouth will apply artificial intelligence and machine learning approaches to extract...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded Beth Israel Deaconess Medical Center, Inc. (BIDMC) $637,845 on June 19, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award funds a remote, randomized controlled study assessing the efficacy of mindfulness apps for people with depression using precision medicine methodology. The research compares participants randomized to...
- The National Institute of Mental Health awarded Trustees of Dartmouth College $114,152 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research determining and enhancing the cellular selectivity of transcranial magnetic stimulation using optical physiology and computational models. The funded research directly tests predictions about how transcranial magnetic stimulation (TMS)—an FDA-approved treatment for drug-resistant depression,...
- The National Institute of Mental Health awarded Dream Face Technologies LLC $314,362 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate robot-administered cognitive behavioral therapy for older adults with depression. Dream Face Technologies will conduct a Phase I Small Business Innovation Research study using the Ryan Companionbot, an AI-powered humanoid socially assistive robot, to assess and treat older adults aged 65 and older with...
- The National Institute of Mental Health awarded Trustees of Dartmouth College $2.366 million on September 11, 2025, under the Mental Health Research Grants program (CFDA 93.242) to investigate the transmission of suicidal thoughts and behaviors among young adults on social media platforms. The research models suicide transmission dynamics on Twitter/X and Reddit using computational social science, Natural Language Processing, dynamic social network analysis, and ecological momentary...
- The National Institute of Mental Health awarded the University of Texas at Austin $171,793 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and test an interactive mobile health chatbot (IPC Trainer) designed to improve the cost-effectiveness and quality of interpersonal counseling delivery by non-specialists treating common mental disorders in community settings in Mozambique. The project addresses two persistent challenges in task-shifted mental...
- The National Institute of Mental Health awarded Beth Israel Deaconess Medical Center, Inc. $2.961 million on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop standardized digital health data formats for mental health research and clinical care. The award funds five integrated aims. Aim 1 establishes a multidisciplinary consortium of clinicians, researchers, industry representatives, regulators, and patient advocates to develop a governance framework...
- The National Institute of Mental Health awarded Brown University $299,660 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate "Chat for Hope," an AI-powered mobile mental health application designed to screen for and address depression, anxiety, and posttraumatic stress symptoms among trauma-exposed adolescents in Ukraine. The project is a collaborative R21/R33 effort between Brown University and the National Academy of...
- The National Institute of Neurological Disorders and Stroke awarded Trustees of Dartmouth College $1,010,880 on May 1, 2026, under the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (CFDA 93.372) to translate a novel carbon-coated neurochemical sensor technology toward integrated neurotransmitter sensing in humans. Dartmouth will develop designs to integrate fast-scan cyclic voltammetry (FSCV)-based dopamine and neuromodulator sensing capabilities into...
- The National Institute of Mental Health awarded the University of California, San Diego $2.115 million on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate a mobile health system delivering just-in-time adaptive interventions based on dialectical behavior therapy principles for young adults with comorbid major depressive disorder, social anxiety disorder, generalized anxiety disorder, and related anxiety conditions. The UNDERSTAND project...
The National Institutes of Health Office of the Director awarded Trustees of Dartmouth College $300,000 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop and pilot test THERABOT+, an enhanced artificial intelligence chatbot for mental health support integrating real-time biofeedback and passive sensing data. THERABOT+ extends prior research on THERABOT, a generative AI chatbot that demonstrated significant symptom reduction in depression and anxiety compared to waitlist control in a randomized controlled trial. The enhanced version incorporates heart rate variability biofeedback collected through smartphone camera during prompted sessions, providing personalized feedback on relaxation techniques including deep breathing and mindfulness exercises. The system also utilizes passive sensing data measuring sleep, activity, and social engagement to personalize interventions and trigger just-in-time adaptive interventions when physiological or behavioral indicators suggest heightened distress. The award supports feasibility research addressing barriers to mental health care access, including cost, stigma, and limited provider availability, by leveraging AI-driven digital interventions capable of dynamic adaptation to individual real-time physiological and behavioral states. Performance occurs in Hanover, New Hampshire, with a period of performance from September 1, 2026, through August 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $300.0k | 9/3/26 |